Clinical Trials
The process from lab to patient
We believe in our science and its potential to change patients’ lives. Clinical trials are a critical step in bringing a new therapy from our in-house laboratory to the world.
Read below for important background information and the most recent updates on our clinical trials. Patients seeking more information on potential clinical trials should contact their physician.
Neuromuscular
OPAL
Spinal Muscular Atrophy
Initiated, recruiting
OPAL is a Phase 2 double-blind study designed to evaluate apitegromab in patients under two years of age who have been or are continuing to be treated with any currently approved SMN therapy, including onasemnogene abeparvovec.
ONYX
Spinal Muscular Atrophy
Active, not recruiting
ONYX is an open-label Phase 3 study designed to assess the long-term safety and efficacy of apitegromab in participants with Type 2 and Type 3 SMA who have completed the TOPAZ or SAPPHIRE trial.
FORGE
Facioscapulohumeral Muscular Dystrophy
Active, recruiting
The FORGE clinical study is evaluating apitegromab, Scholar Rock’s investigational muscle-targeted treatment, to find out how it impacts muscle size and function in people with FSHD, and how well it works compared to a placebo. Doctors also want to learn how people respond to apitegromab and how safe it is.
Expanded Access Policy
View Our Expanded Access Policy
Patients seeking more information on potential clinical trials should contact their physician.